NewGenIvf Group Limited (NASDAQ: NIVF) shares gained 28.51% to $0.13 in after-hours trading on Thursday. This surge followed the announcement that the company closed its reasonable best efforts public offering with gross proceeds of approximately $1.25 million.

The transaction, which concluded on September 30, 2026, comprised 17,857,143 Class A Ordinary Shares or Pre-Funded Warrants in lieu thereof. Specifically, this included 125,000 Class A Ordinary Shares and Pre-Funded Warrants to purchase up to 17,732,143 Class A Ordinary Shares. The public offering price was set at $0.07 per Class A Ordinary Share and $0.06999 per Pre-Funded Warrant, reflecting an exercise price of $0.00001 per warrant. These warrants are immediately exercisable until exercised in full.

Use of Proceeds and Strategic Allocation

The company intends to deploy the net proceeds, combined with existing cash resources, across several strategic initiatives. Key allocations include:

• Investment in K25.ai
• Restructuring of debt securities
• Working capital for manufacturing and deployment of Nodexus machines in the cell-sorting business
• General corporate purposes

Regulatory and Advisory Details

The offering was conducted under a registration statement on Form F-1 (No. 333-298442), filed with the U.S. Securities and Exchange Commission (SEC) on August 20, 2026, and declared effective on September 28, 2026. Aegis Capital Corp. served as the exclusive placement agent. Han Kun Law Offices LLP acted as U.S. counsel to the company, while Kaufman & Canoles, P.C. represented Aegis Capital Corp.

Market Performance and Technical Indicators

Despite the after-hours gain, NIVF stock closed the regular session at $0.10, down 39.88%. The company has a market capitalization of approximately $209,870. Over the past 12 months, the small-cap stock has fallen 99.99%, trading between a 52-week high of $1,539 and a 52-week low of $0.06. Benzinga’s Edge Stock Rankings indicate a negative price trend across all time frames, and the Relative Strength Index (RSI) stands at 19.83.

What the Numbers Show

The pricing structure highlights a significant reliance on equity dilution to fund operational pivots. With gross proceeds fixed at $1.25 million against a low share price of $0.07, the issuance of over 17.8 million units indicates substantial expansion of the outstanding share count. This capital injection is explicitly directed toward non-core diversification (K25.ai) and liability management (debt restructuring), suggesting a strategic shift to balance immediate financial obligations with long-term technological investments. The divergence between the regular session drop of 39.88% and the after-hours rise of 28.51% reflects high volatility and potential speculative reaction to the capital raise amidst a broader downtrend.

NewGenIvf Group has approved a 1-for-3 reverse stock split. The corporate action was disclosed via an SEC filing.

The filing confirms the board's decision to consolidate shares, reducing the total number of outstanding shares by two-thirds while proportionally increasing the value of each remaining share. No specific effective date or financial impact metrics were included in the provided source material.

Corporate Action Details

The key parameters of the approved action are as follows:

• Action Type: Reverse Stock Split
• Ratio: 1-for-3
• Source Disclosure: SEC Filing